Neurology · Phase 2
LIXIPARK: early Parkinson disease
What was tested?
Lixisenatide versus placebo alongside stable treatment for Parkinson symptoms. ↗
Registered primary question: Change in the MDS-UPDRS part III motor score at month 12. ↗
What the reviewed report found
Journal year 2024 · Article summary reviewed 2026-09-15
The between-group difference in motor-score change at 12 months was 3.08 points favoring lixisenatide. Nausea occurred in 46% and vomiting in 13% of active-group participants.↗
Keep in context: The primary assessment was performed while participants were taking their Parkinson medication. The two-month washout assessment is a different time point and does not establish durable disease modification. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 156 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 40 Years to 75 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2025-11-28; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
LIXIPARK: exploratory Parkinson trial
- Design in the report
- Randomized, double-blind, placebo-controlled phase 2 trial with 12 months of treatment and a two-month washout.↗
- Participants in the report
- 156 people with early Parkinson disease were randomized while receiving stable symptomatic therapy.↗
- Limitations
- The primary assessment was in the on-medication state. A small phase 2 study cannot establish disease modification, long-term benefit or safety; larger trials are required.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease ↗
Protocol identifier: RC31/16/8912. Sponsor: University Hospital, Toulouse.
Retrieved 2026-09-20; SHA-256 4b20e2492df624bfcc7faedd9d6abf1d2f2aeb38640fbe2a768d967a0f1e01cb.
PMID 38598572
Trial of Lixisenatide in Early Parkinson's Disease. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 38598572. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 1c89844dd46e395e8dfdf02f0b578335e189cb034eb66edd1a1a3f0fb7c169f7.